Ocular Therapeutix, Inc. OCUL R2KR3KPHARMA
Company Overview
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
Why Investors Should Care
Revenue has grown at a 104.0% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.15.
Recent Developments
- Dec 2025 Revenue of $51.95M (-18.5% YoY); net profit $-265.94M.
- Trailing 12 Months Year-on-year growth — revenue +0.1%.
- 5-Year Trend Long-term compounding — revenue CAGR 104.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 104.00% |
| 1 Year: | 0.10% |
Stock Price Performance
| 1 Year: | -14.88% |
| 6 Months: | +3.60% |
| 3 Months: | +28.97% |
| 1 Month: | +21.74% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)56.09 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 104.0% over 5 years.
CONS
- Trading 34.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | OCUL Ocular Therapeutix, Inc. R2KR3KPHARMA | 10.64 | -7.60 | $2.34B | 0.00% | -35.66% | -72.99% | 104.00% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | 340.00K | 648.00K | 498.00K | 504.00K | 492.00K | 650.00K | 829.00K | 2.26M | 2.61M | 1.57M | 5.88M | 7.34M | 11.72M | 12.15M | 13.19M | 12.27M | 11.96M | 13.37M | 15.19M | 15.08M | 14.77M | 16.44M | 15.43M | 10.70M | 13.46M | 14.54M | 10.79M | 13.47M |
| Operating Income | -7.11M | -9.63M | -11.17M | -10.28M | -10.51M | -11.11M | -9.24M | -12.47M | -15.67M | -18.34M | -15.20M | -12.72M | -13.46M | -13.56M | -14.82M | -17.28M | -19.66M | -21.60M | -23.14M | -21.40M | -16.61M | -17.88M | -14.01M | -20.23M | -20.23M | -19.53M | -17.83M | -19.92M | -21.54M | -22.55M | -20.57M | -19.21M | -31.62M | -43.59M | -46.00M | -63.92M | -67.64M | -68.70M | -93.34M | -82.11M |
| Net Income | -7.58M | -10.01M | -11.52M | -10.64M | -10.84M | -11.45M | -9.60M | -12.82M | -16.02M | -18.69M | -15.57M | -13.10M | -13.77M | -13.80M | -15.01M | -17.40M | -17.12M | -24.45M | -18.78M | -26.02M | -21.51M | -36.57M | -11.94M | 3.12M | -8.48M | 2.66M | -12.54M | -18.77M | -24.19M | -30.32M | -20.68M | -516.00K | -64.85M | -43.78M | -36.49M | -64.05M | -67.81M | -69.42M | -88.61M | -78.76M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | -0.40 | -0.37 | -0.38 | -0.42 | -0.45 | -0.57 | -0.45 | -0.53 | -0.41 | -0.64 | -0.21 | -0.24 | -0.25 | -0.23 | -0.22 | -0.25 | -0.31 | -0.39 | -0.26 | -0.25 | -0.49 | -0.26 | -0.22 | -0.38 | -0.39 | -0.38 | -0.40 | -0.35 |
| R&D Expense | 4.72M | 6.74M | 8.26M | - | 7.07M | 6.98M | 5.69M | - | 6.73M | 8.12M | 8.13M | - | 8.23M | 8.74M | 9.69M | - | 11.32M | 9.41M | 10.23M | - | 6.10M | 8.02M | 6.95M | 10.93M | 13.86M | 12.72M | 13.10M | 13.10M | 13.72M | 14.75M | 15.09M | 15.02M | 20.73M | 28.86M | 37.05M | 42.86M | 51.08M | 52.36M | 66.21M | 54.14M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 10.00K | - | 772.00K | 1.75M | 1.89M | 1.92M | 1.99M | 4.23M | 17.40M | 43.52M | 51.49M | 58.44M | 63.72M | 51.95M |
| Operating Income | -13.67M | -12.90M | -27.09M | -38.20M | -43.33M | -61.92M | -59.12M | -85.80M | -62.85M | -78.04M | -78.65M | -82.38M | -171.78M | -270.02M |
| Net Income | -14.09M | -13.32M | -28.65M | -39.75M | -44.70M | -63.39M | -59.98M | -86.37M | -155.64M | -6.55M | -71.04M | -80.74M | -193.51M | -265.94M |
| Diluted EPS | - | - | - | - | - | - | - | -1.91 | -2.56 | -0.98 | -0.97 | -1.02 | -1.22 | -1.42 |
| R&D Expense | 11.54M | 10.52M | 18.88M | 26.61M | 27.07M | 30.88M | 36.91M | 41.09M | 28.69M | 50.08M | 53.46M | 61.05M | 127.64M | 197.10M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 19.15M | 78.19M | 110.31M | 74.94M | 55.43M | 73.04M | 78.74M | 261.86M | 204.89M | 149.29M | 252.06M | 457.94M | 808.06M |
| Total Equity | -32.73M | -46.61M | -59.47M | 58.70M | 89.59M | 52.01M | 26.15M | 35.88M | -3.63M | 76.09M | 88.00M | 35.38M | 91.13M | 315.34M | 654.31M |
| Cash & Equivalents | 5.33M | 23.85M | 17.50M | 37.39M | 30.78M | 32.94M | 41.54M | 54.06M | 54.44M | 228.06M | 164.16M | 102.30M | 195.81M | 392.10M | 737.06M |
| Total Liabilities | - | - | 4.27M | 19.50M | 20.72M | 22.93M | 29.28M | 37.17M | 82.37M | 185.77M | 116.89M | 113.91M | 160.93M | 142.59M | 153.75M |
| Current Liabilities | - | - | 3.34M | 5.87M | 5.38M | 8.30M | 13.43M | 9.16M | 12.03M | 26.66M | 26.34M | 31.39M | 34.90M | 41.35M | 50.81M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | -33.74M | -34.00M | -50.47M | -49.23M | -77.58M | -53.55M | -65.55M | -59.60M | -70.23M | -134.68M | -204.88M |
| Investing Cash Flow | - | - | - | -38.57M | 37.07M | 26.95M | -1.89M | -2.24M | -841.00K | -1.19M | -3.71M | -6.09M | -1.29M | -11.88M |
| Financing Cash Flow | - | - | - | 65.70M | 585.00K | 32.01M | 68.64M | 75.34M | 228.01M | 2.85M | 1.45M | 169.83M | 332.11M | 561.72M |
| Capital Expenditure | -203.00K | -387.00K | -1.26M | -1.78M | -1.92M | -8.25M | -1.89M | -2.24M | -841.00K | -1.19M | -3.71M | -6.09M | -1.29M | -12.01M |
| Free Cash Flow | - | - | - | -35.52M | -35.92M | -58.73M | -51.12M | -79.82M | -54.40M | -66.74M | -63.32M | -76.32M | -135.97M | -216.89M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | -136,710.0% | - | -3,509.6% | -2,182.7% | -2,296.0% | -3,220.1% | -2,970.8% | -2,029.9% | -361.1% | -179.3% | -152.7% | -141.0% | -269.6% | -519.8% |
| Net Margin % | -140,930.0% | - | -3,710.9% | -2,271.3% | -2,369.0% | -3,296.2% | -3,014.0% | -2,043.3% | -894.3% | -15.1% | -138.0% | -138.1% | -303.7% | -511.9% |
| ROE % | 30.2% | 22.4% | -48.8% | -44.4% | -86.0% | -242.4% | -167.2% | 2,379.4% | -204.5% | -7.4% | -200.8% | -88.6% | -61.4% | -40.6% |
| ROCE % | - | -81.6% | -37.5% | -36.4% | -65.0% | -147.4% | -92.5% | -128.6% | -26.7% | -43.7% | -66.7% | -37.9% | -41.2% | -35.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 14.96% | 32.84M | $340.26M |
| 2 | Deep Track Capital, Lp | 8.96% | 19.69M | $203.95M |
| 3 | Blackrock Inc. | 8.82% | 19.38M | $200.74M |
| 4 | Avoro Capital Advisors LLC | 5.71% | 12.54M | $129.91M |
| 5 | Summer Road LLC | 5.56% | 12.21M | $126.48M |
| 6 | Venrock Adviser, LLC | 4.71% | 10.35M | $107.19M |
| 7 | Vanguard Capital Management LLC | 4.02% | 8.83M | $91.51M |
| 8 | Price (T.Rowe) Associates Inc | 3.47% | 7.62M | $78.98M |
| 9 | Logos Global Management LP | 2.41% | 5.30M | $54.91M |
| 10 | State Street Corporation | 2.38% | 5.23M | $54.22M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for OCUL
OCUL Stock Is Climbing Ahead Of Investor Day — What Is On The Agenda? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMiygFBVV95cUxQX1FnWlRKMEk1X0pYSndQOF95RkQ2VlltRmlsc0hDajF3dTZfczhZcHQzNVFKY210dm1OYzlSOTlaSXlvaWNMNXZXNUluWTBoRmY0QTN0bzhwYVFNbWdrV0VGdk1KMWs2NlBFZU9SdER5LWd2cGdZbUMzUWVjZHB2RVBDLWNJYWRMbHdBMT…
Ocular Therapeutix (OCUL) Stock Fair Value Edges Higher After Analyst Target Increases - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxPX0NJTExjQ2VnZGM2Z3RESTkwemZ3M2ZaTmE4a2pfamlGSVhQNG5COWg1Ny1mYVpLeG54bXRuaXRlMG9iSlZwTkZBTGFxV3lfSC1JXzlSZ2h2emVUV3FPbUF0TWNzaG50bk5PZGpkZWtpOTlGSTVMLVV6cTNfcTYzSDd4b04tZFpJUWc1U1…
Ocular Therapeutix Stock Price Forecast. Should You Buy OCUL? - StockInvest.us
<a href="https://news.google.com/rss/articles/CBMiSEFVX3lxTE0za0huY1BLYXVpN0FIamxhdjVlVnBuY2VNMzFqYVEwVV9fQWM3NGZlMlo5UVpCX2lZaElyZ1BfQ19IbVQ3UjFySQ?oc=5" target="_blank">Ocular Therapeutix Stock Price Forecast. Should You Buy OCUL?</a>&nbs…
What Ocular Therapeutix (OCUL)'s AXPAXLI NDA Timeline and FDA Feedback Means For Shareholders - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi5wFBVV95cUxOdkkzalh6WVEzOFJOcXBqZXBvUzRDTzVoVW9BNmNtc2s4eEs2X3o3dG1hc0psMnI3MjEydmdtZHNKOU5LeHBQQU8wMXJnVEFmYlA0OUFwM3AtTmdjZnAybnczNWFvSU91ZGpLWXhucHZUak5PQ0JKSlNZQUxITUNFTGV2X01DbEQzVm1ueU…
Ocular Therapeutix™ to Participate in September and October Investor and Scientific Conferences - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxNY0c3RmpUMDVlVXRHWXktejc0S2p1b3RXcVFiWG5TZlUzeVhWSURYdjhrUGp1SjBzQ25aZUV3MndtbjFUQmxKb2FUd0J6RmRnMzQzeW5PcE8tdW1rQ2I0WllNZHpyN0Z0di15NHlWYi0zS2dZOUZfaHZLd0Uyc0F1cEdkbldPMTUzc0NPU2…
(OCUL) and the Role of Price-Sensitive Allocations - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxNeWpJMnNqODdNOE5OVzk4azV5V3ZVdzNkZ3BPckt5cWVrS2Z2UVlmMW85emE1aWZYS0QzT3RfdHBqTnluM0F6enMxZGlhbF9XX282TmZyR3dqd0dJT2JXdWM2MnJxeGMzMms0RWlmVWJzT2k1c0xhbkdIbXRUSzJJOHk1S0VYeklVRDdmMl…
OCUL — Frequently Asked Questions
What is the current share price of Ocular Therapeutix, Inc. (OCUL)?
As of 2026-09-07 16:24 PDT, Ocular Therapeutix, Inc. (OCUL) trades at $10.64 on NasdaqGM. Its 52-week range is $6.88 to $16.11.
What is the market capitalisation of OCUL?
Ocular Therapeutix, Inc. (OCUL) has a market capitalisation of $2.34B on NasdaqGM.
What is the P/E ratio of OCUL?
OCUL trades at a trailing price-to-earnings (P/E) ratio of -7.60. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 3.46.
What is the return on equity (ROE) of OCUL?
OCUL has a return on equity (ROE) of -72.99%. Its return on capital employed (ROCE) is -35.66%.
Is OCUL a good stock to buy?
This page provides a data-driven analysis of Ocular Therapeutix, Inc. (OCUL), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.